Literature DB >> 26621221

The complex role of NOTCH receptors and their ligands in the development of hepatoblastoma, cholangiocarcinoma and hepatocellular carcinoma.

Borja Gil-García1, Victoriano Baladrón1.   

Abstract

The NOTCH signalling pathway is one of the key molecular pathways of embryonic development and adult tissues homeostasis in mammals. Mammals have four NOTCH receptors and various ligands that modulate their activity. Many cell disorders, whose genesis involves the NOTCH signalling pathway, have been discovered, including cancer. The mechanisms by which these receptors and their ligands affect liver cell transformation are not yet well understood, and they seem to behave as both oncogenes and tumour-suppressor proteins. In this review, we discuss the published data regarding the role of these proteins in the development of hepatoblastoma, cholangiocarcinoma and hepatocellular carcinoma malignancies. The alteration of the NOTCH signalling pathway may be one of the main drivers of hepatic neoplastic growth. However, this signalling pathway might also modulate the development of specific liver tumour features. The complexity of the function of NOTCH receptors and their ligands may be due to their interactions with many other cell signalling pathways. Furthermore, the different levels of expression and activation of these receptors could be a reason for their distinct and sometimes contradictory effects.
© 2015 Société Française des Microscopies and Société de Biologie Cellulaire de France. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Cholangiocarcinoma (CC); Hepatoblastoma (HBT); Hepatocellular carcinoma (HCC); Liver cancer; NOTCH ligand; NOTCH receptor

Mesh:

Substances:

Year:  2015        PMID: 26621221     DOI: 10.1111/boc.201500029

Source DB:  PubMed          Journal:  Biol Cell        ISSN: 0248-4900            Impact factor:   4.458


  19 in total

1.  MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer.

Authors:  Valeria Canu; Andrea Sacconi; Laura Lorenzon; Francesca Biagioni; Federica Lo Sardo; Maria Grazia Diodoro; Paola Muti; Alfredo Garofalo; Sabrina Strano; Antonietta D'Errico; Gian Luca Grazi; Mario Cioce; Giovanni Blandino
Journal:  Oncotarget       Date:  2017-05-02

Review 2.  Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis.

Authors:  Yeliz Yılmaz; Ayşim Güneş; Hande Topel; Neşe Atabey
Journal:  J Gastrointest Cancer       Date:  2017-09

3.  Molecular Mechanisms of Hepatoblastoma.

Authors:  Yi Zhang; Antonio Solinas; Stefano Cairo; Matthias Evert; Xin Chen; Diego F Calvisi
Journal:  Semin Liver Dis       Date:  2021-01-20       Impact factor: 6.115

4.  Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans.

Authors:  L Che; B Fan; M G Pilo; Z Xu; Y Liu; A Cigliano; A Cossu; G Palmieri; R M Pascale; A Porcu; G Vidili; M Serra; F Dombrowski; S Ribback; D F Calvisi; X Chen
Journal:  Oncogenesis       Date:  2016-12-05       Impact factor: 7.485

Review 5.  Targeting Notch3 in Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Perspectives.

Authors:  Catia Giovannini; Luigi Bolondi; Laura Gramantieri
Journal:  Int J Mol Sci       Date:  2016-12-28       Impact factor: 5.923

6.  Clinical significance of chromodomain helicase/ATPase DNA binding protein 1-like and human mutL homolog 1 gene expression in cholangiocarcinoma.

Authors:  Jingwen Hua; Shiniao Li; Changwen Huang
Journal:  Oncol Lett       Date:  2018-06-28       Impact factor: 2.967

7.  CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib.

Authors:  Guang-Ang Tian; Chun-Chao Zhu; Xiao-Xin Zhang; Lei Zhu; Xiao-Mei Yang; Shu-Heng Jiang; Rong-Kun Li; Lin Tu; Yang Wang; Chun Zhuang; Ping He; Qing Li; Xiao-Yan Cao; Hui Cao; Zhi-Gang Zhang
Journal:  Sci Rep       Date:  2016-08-10       Impact factor: 4.379

8.  Epigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation.

Authors:  Yin-Cheng Huang; Sheng-Jia Lin; Hung-Yu Shih; Chung-Han Chou; Hsiao-Han Chu; Ching-Chi Chiu; Chiou-Hwa Yuh; Tu-Hsueh Yeh; Yi-Chuan Cheng
Journal:  Oncotarget       Date:  2017-06-27

9.  Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.

Authors:  Serena Mancarella; Grazia Serino; Francesco Dituri; Antonio Cigliano; Silvia Ribback; Jingxiao Wang; Xin Chen; Diego F Calvisi; Gianluigi Giannelli
Journal:  Cell Death Differ       Date:  2020-02-10       Impact factor: 15.828

10.  Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.

Authors:  Jingxiao Wang; Mingjie Dong; Zhong Xu; Xinhua Song; Shanshan Zhang; Yu Qiao; Li Che; John Gordan; Kaiwen Hu; Yan Liu; Diego F Calvisi; Xin Chen
Journal:  Oncogene       Date:  2018-03-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.